I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024

I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.

https://mma.prnewswire.com/media/2377824/I_MAB_Logo.jpg

Piper Sandler 36th Annual Healthcare Conference Presentation Details

Presentation Time Wednesday, December 4 at4:30 p.m. ETPresenters Sean Fu, PhD, MBA, Chief Executive Officer Phillip Dennis, MD, PhD, Chief Medical OfficerWebcast link HereMeetings One-on-one and small group meetings:December 3 – 4, 2024Management Sean Fu, PhD, MBA, Chief Executive OfficerParticipants Joseph Skelton, Chief Financial Officer Phillip Dennis, MD, PhD, Chief Medical Officer Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under “Event Calendar” onI-Mab'sIR websiteathttps://ir.i-mabbiopharma.com/

For more information, please contact your Piper Sandler representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact:

Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com

https://c212.net/c/img/favicon.png?sn=CN62966&sd=2024-11-21

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-piper-sandler-healthcare-conference-302312202.html

SOURCE I-Mab Biopharma

https://rt.newswire.ca/rt.gif?NewsItemId=CN62966&Transmission_Id=202411210700PR_NEWS_USPR_____CN62966&DateId=20241121